BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Table 1 BACE1 knockout mouse phenotypes

Phenotype	Putative Substrate	References
Astrogenesis increase; neurogenesis decrease	Jag1	[46]
Axon guidance defects	CHL1	[36]-[38]
Hyperactivity	NRG1	[29],[48]
Hypomyelination	NRG1	[39]-[41]
Memory deficits	Unknown	[17],[30],[32],[42],[43]
Insulin sensitivity enhanced	Unknown	[29],[51],[52]
Muscle spindle reduction	NRG1	[44]
Neurochemical deficits	Unknown	[45]
Neurodegeneration with age	Unknown	[47]
Postnatal lethality, growth retardation	Unknown	[29]
Retinal abnormalities	VEGFR1	[49]
Schizophrenia endophenotypes	NRG1	[48]
Seizures	Na_vβ₂	[42],[47],[50],[53]
Spine density reduction	NRG1	[48]
BACE2 knockout mouse phenotypes
Phenotype	Putative Substrate	References
Normal	---	[29]
Pancreatic β cell increase	Tmem27	[54]
Pigmentation abnormalities	PMEL	[55]
BACE1/2 double knockout mouse phenotypes
Phenotype		References
Similar to BACE1 knockout, except postnatal lethality is enhanced		[29]

ISSN: 1758-9193